Gennova Biopharmaceuticals, in partnership with CEPI, will advance the development of a self-amplifying mRNA vaccine against ...

Emcutix Biopharmaceuticals has signed an exclusive in-licensing agreement with WiQo for PRX-PLUS, a non-invasive skin tightening treatment. The deal will allow Emcutix to import, promote, and ...

Currently there are no authorized vaccines or targeted drugs against Nipah, which kills an estimated 75% of those it infects.

Gennova Biopharmaceuticals Ltd. on Tuesday announced that it is partnering with the Coalition for Epidemic Preparedness Innovations (CEPI), a subsidiary of Emcure Pharmaceuticals Ltd. for the ...

Under the partnership agreement, Emcutix Biopharmaceuticals has the right to import and sell 'PRX-PLUS', a skin-tightening ...

Emcure Pharmaceuticals shares gained 2% after its subsidiary entered into a partnership with WiQo to distribute the ...

Emcutix Biopharmaceuticals, a wholly owned subsidiary of Emcure Pharmaceuticals, announced an exclusive in-licensing agreement with WiQo, an innovative Italian derma-cosmetic and medical device ...

Pune: Emcure Pharmaceuticals Ltd. subsidiary Gennova Biopharmaceuticals Ltd., is advancing the development of a pathbreaking ...

Dr Sanjay Singh, CEO of Gennova Biopharmaceuticals, said the firm will do preclinical and phase 1 vaccine tests in India, ...